REG - BiVictriX Therapcts. - BiVictriX identifies lead for BVX001 programme

Bivictrix TherapeuticsAnnouncement

07/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221207:nRSG8267Ia&default-theme=true

RNS Number : 8267I  BiVictriX Therapeutics PLC  07 December 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company" or the "Group")

BiVictriX identifies development lead for BVX001 programme

Lead identified for the BVX001 programme which demonstrates encouraging
potency and enhanced cancer selectivity

Lead will now be progressed to in vivo studies to obtain readouts on
preclinical efficacy and safety

Alderley Park, 7 December 2022 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, announces that it has identified a development lead for its BVX001
programme (the "Lead").

The Lead was developed using BiVictriX's proprietary Bi-Cygni® approach,
which aims to generate the next-generation of Antibody Drug Conjugates
("ADCs") with superior cancer selectivity. The Lead was selected based on
promising in vitro potency and cancer cell selectivity data, together with
encouraging data reported from a panel of ex-vivo safety assays using healthy
human cells.

The Lead, together with backup candidates, will now be taken forward into a
panel of in vivo models. These will include models of Acute Myeloid Leukaemia
to investigate the optimum dose of the molecule.  In addition, the Lead will
be assessed in safety models providing indicative safety data for the
programme. Results from these experiments, in addition to the data already
obtained, will support manufacturing preparations and guide future clinical
trials.

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc,
commented: "We are delighted to be able to announce that we have identified a
lead compound for our BVX001 programme, in line with what we set out to do
earlier this year. This marks a significant step forward towards progressing
this programme to the clinic, where we hope to deliver key outcomes for
patients who currently have limited options. This announcement also comes at a
time when interest in the ADC sector is on the rise with over 12
deals/partnerships announced this year alone. I would like to thank the team
at BiVictriX for all their hard work in achieving this fundamental milestone.
"

 

 

For more information, please contact:

 BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                             Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)               Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon  (UK) Limited (Joint Broker)                     Tel: +44 (0) 20 7886 2500
 Rupert Dearden, Freddy Crossley, Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Namrata Taak, Genevieve Wilson, Alex Gunter  Tel: +44 (0) 20 3709 5700

                                                                 Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related harmful side effects.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
cancer-specific antigen pairs, or "twin antigens fingerprints", on tumour
cells, which are largely absent from healthy cells. Whereas this concept has
been validated in a clinical diagnostic setting to support the diagnosis and
monitoring of haematological cancers, it has not yet been widely used in a
therapeutic setting, where it offers the opportunity to be a game-changing
approach to cancer care.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens fingerprints" across a broad range of cancer indications. The Company
is using these novel twin antigens to develop more effective and safer
therapeutics to target cancers that are expected to constitute orphan
indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGBDDIGGDGDL